NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Silo Pharma, Inc. SILO
11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-4.2M
Growth
USD 72,102.00
Revenue, FY2025 · full 11-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.1 · Net income -4.2
Compound annual growth
Revenue compounded at +12.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−5863 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -5937.0% · Net -5863.5%
ROE
FY2025 · ROE -74.6%
Each USD of equity lost 75 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | · | · | · | · | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.50 | −1.19 | −1.20 | · | 0.04 | −0.05 | −0.04 | −0.02 | 0.01 | 0.00 | 0.00 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −74.6 | −78.4 | −44.8 | −40.3 | 75.5 | −483.0 | −527.0 | −120.4 | 29.6 | · | · |
| Shares out B | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.02 | 0.02 | 0.05 | 0.03 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 49 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 46 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011